Trained Innate Immunity Not Always Amicable
Abstract
:1. Introduction
2. Atherosclerosis
3. Diabetes Mellitus
4. Chronic Inflammatory Disorders
4.1. Rheumatoid Arthritis
4.2. Systemic Lupus Erythematosus
4.3. Multiple Sclerosis
4.4. Sarcoidosis
5. Neurodegenerative Disorders
5.1. Alzheimer’s Disease
5.2. Parkinson’s Disease
5.3. Autism Spectrum Disorder
6. Conclusions
Author Contributions
Funding
Conflicts of Interest
Abbreviations
ABCA1 | cholesterol efflux regulatory protein |
ABCG1 | intracellular cholesterol transporting protein |
BCG | M. bovis BCG (Bacillus Calmette-Guérin) |
GM-CSF | granulocyte-monocyte colony stimulating factor |
CXCL | chemokine (C-X-C) ligand |
DNMT | DNA methyltransferase |
HAT | acetyltransferase |
HDAC | histone deacetylase |
HDM | histone demethylase |
HLA | human leukocyte antigen |
HMT | histone methyltransferase |
ICAM-1 | Intracellular adhesion molecule 1 |
IFN | interferon |
IL | interleukin |
IRAK | interleukin-1 receptor associated kinase |
LPS | lipopolysaccharide |
MBP | myelin basic protein |
MCP-1 | monocyte chemoattractant protein-1 |
MHC | major histocompatibility complex |
MMP | metalloproteinase |
NK | Natural killer cell |
oxLDL | oxidized low-density lipoprotein |
PADI2 | peptidyl arginine deaminase 2 |
Pam3Cys | tripalmitoyl-S-glyceryl cysteine |
PPARG1 | pepxisome proliferator-activated receptor gamma |
ROS | reactive oxygen species |
SUMO | small ubiquitin-like modifier |
TGF-beta | transforming growth factor |
Th | T helper cell |
TLR | Toll-like receptor |
TNF | tumor necrosis factor |
TSA | trichostatin A |
VCAM-1 | vascular cell adhesion molecule 1 |
References
- Netea, M.G.; van der Meer, J.W. Trained immunity: An ancient way of remembering. Cell Host Microbe 2017, 21, 297–300. [Google Scholar] [CrossRef]
- Benn, C.S.; Netea, M.G.; Selin, L.K.; Aaby, P. A small jab–A big effect: Nonspecific immunomodulation by vaccines. Trends Immunol. 2013, 34, 431–439. [Google Scholar] [CrossRef]
- Rusek, P.; Wala, M.; Druszczyńska, M.; Fol, M. Infectious agents as stimuli of trained innate immunity. Int. J. Mol. Sci. 2018, 19, 456. [Google Scholar] [CrossRef] [PubMed]
- Aaby, P.; Roth, A.; Ravn, H.; Napirna, B.M.; Rodrigues, A.; Lisse, I.M.; Stensballe, L.; Diness, B.R.; Lausch, K.R.; Lund, N.; et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: Beneficial nonspecific effects in the neonatal period? J. Infect. Dis. 2011, 204, 245–252. [Google Scholar] [CrossRef] [PubMed]
- Bowdish, D.M.; Loffredo, M.S.; Mukhopadhyay, S.; Mantovani, A.; Gordon, S. Macrophage receptors implicated in the “adaptive” form of innate immunity. Microbes Infect. 2007, 9, 1680–1687. [Google Scholar] [CrossRef] [PubMed]
- Sun, J.C.; Beilke, J.N.; Lanier, L.L. Adaptive immune features of natural killer cells. Nature 2009, 457, 557–561. [Google Scholar] [CrossRef]
- Netea, M.G.; Quintin, J.; van der Meer, J.W. Trained immunity: A memory for innate host defense. Cell Host Microbe 2011, 9, 355–361. [Google Scholar] [CrossRef] [PubMed]
- Quintin, J.; Saeed, S.; Martens, J.H.A.; Giamarellos-Bourboulis, E.J.; Ifrim, D.C.; Logie, C.; Jacobs, L.; Jansen, T.; Kullberg, B.J.; Wijmenga, C.; et al. Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe 2012, 12, 223–232. [Google Scholar] [CrossRef] [PubMed]
- Netea, M.G.; Joosten, L.A.; Latz, E.; Mills, K.H.; Natoli, G.; Stunnenberg, H.G.; O’Neill, L.A.; Xavier, R.J. Trained immunity: A program of innate immune memory in health and disease. Science 2016, 352, aaf1098. [Google Scholar] [CrossRef]
- Christ, A.; Bekkering, S.; Latz, E.; Riksen, N.P. Long-term activation of the innate immune system in atherosclerosis. Semin. Immunol. 2016, 28, 384–393. [Google Scholar] [CrossRef] [Green Version]
- Bekkering, S.; van den Munckhof, I.; Nielen, T.; Lamfers, E.; Dinarello, C.; Rutten, J.; de Graaf, J.; Joosten, L.A.; Netea, M.G.; Gomes, M.E.; et al. Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo. Atherosclerosis 2016, 254, 228–236. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hansson, G.K.; Hermansson, A. The immune system in atherosclerosis. Nat. Immunol. 2011, 12, 204–212. [Google Scholar] [CrossRef] [PubMed]
- Bekkering, S.; Quintin, J.; Joosten, L.A.; van der Meer, J.W.; Netea, M.G.; Riksen, N.P. Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes. Arterioscler. Thromb. Vasc. Biol. 2014, 34, 1731–1738. [Google Scholar] [CrossRef] [PubMed]
- Nicorescu, I.; Dallinga, G.M.; de Winther, M.P.J.; Stroes, E.S.G.; Bahjat, M. Potential epigenetic therapeutics for atherosclerosis treatment. Atherosclerosis 2019, 281, 189–197. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Neele, A.E.; Van den Bossche, J.; Hoeksema, M.A.; de Winther, M.P. Epigenetic pathways in macrophages emerge as novel targets in atherosclerosis. Eur. J. Pharmacol. 2015, 763, 79–89. [Google Scholar] [CrossRef]
- Meier, B.C.; Wagner, B.K. Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics. Epigenomics 2014, 6, 209–214. [Google Scholar] [CrossRef] [PubMed]
- Jerram, S.T.; Dang, M.N.; Leslie, R.D. The role of epigenetics in type 1 diabetes. Curr. Diab. Rep. 2017, 10, 89. [Google Scholar] [CrossRef]
- Davegårdh, C.; García-Calzón, S.; Bacos, K.; Ling, C. DNA methylation in the pathogenesis of type 2 diabetes in humans. Mol. Metab. 2018, 14, 12–25. [Google Scholar] [CrossRef]
- Miao, F.; Smith, D.D.; Zhang, L.; Min, A.; Feng, W.; Natarajan, R. Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: An epigenetic study in diabetes. Diabetes 2008, 12, 3189–3198. [Google Scholar] [CrossRef]
- Nano, J.; Fernandez, E.P.; Troup, J.; Ghanbari, M.; Franco, O.H.; Muka, T. Epigenetics of diabetes in humans. In Epigenetics in Human Disease, 2nd ed.; Tollefsbol, T., Ed.; Academic Press: Cambridge, MA, USA, 2018; Volume 6, pp. 457–488. [Google Scholar]
- Barajas-Olmos, F.; Centeno-Cruz, F.; Zerrweck, C.; Imaz-Rosshandler, I.; Martínez-Hernández, A.; Cordova, E.J.; Rangel-Escareño, C.; Gálvez, F.; Castillo, A.; Maydón, H.; et al. Altered DNA methylation in liver and adipose tissues derived from individuals with obesity and type 2 diabetes. BMC Med. Genet. 2018, 1, 28. [Google Scholar] [CrossRef]
- Van Diepen, J.A.; Thiem, K.; Stienstra, R.; Riksen, N.P.; Tack, C.J.; Netea, M.G. Diabetes propels the risk for cardiovascular disease: Sweet monocytes becoming aggressive? Cell Mol. Life Sci. 2016, 73, 4675–4684. [Google Scholar] [CrossRef]
- Lachmandas, E.; Vrieling, F.; Wilson, L.G.; Joosten, S.A.; Netea, M.G.; Ottenhoff, T.H.; van Crevel, R. The effect of hyperglycaemia on in vitro cytokine production and macrophage infection with Mycobacterium tuberculosis. PLoS ONE 2015, 10, e0117941. [Google Scholar] [CrossRef]
- Crișan, T.O.; Netea, M.G.; Joosten, L.A. Innate immune memory: Implications for host responses to damage-associated molecular patterns. Eur. J. Immunol. 2016, 46, 817–828. [Google Scholar] [CrossRef]
- Saeed, S.; Quintin, J.; Kerstens, H.H.; Rao, N.A.; Aghajanirefah, A.; Matarese, F.; Cheng, S.C.; Ratter, J.; Berentsen, K.; van der Ent, M.A.; et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science 2014, 345, 1251086. [Google Scholar] [CrossRef]
- Klein, K.; Ospelt, C.; Gay, S. Epigenetic contributions in the development of rheumatoid arthritis. Arthritis Res. Ther. 2012, 14, 227. [Google Scholar] [CrossRef]
- Maciejewska Rodrigues, H.; Jüngel, A.; Gay, R.E.; Gay, S. Innate immunity, epigenetics and autoimmunity in rheumatoid arthritis. Mol. Immunol. 2009, 47, 12–18. [Google Scholar] [CrossRef] [Green Version]
- Álvarez-Errico, D.; Vento-Tormo, R.; Ballestar, E. Genetic and epigenetic determinants in autoinflammatory diseases. Front. Immunol. 2017, 8, 318. [Google Scholar] [CrossRef]
- Arts, R.J.W.; Joosten, L.A.B.; Netea, M.G. The potential role of trained immunity in autoimmune and autoinflammatory disorders. Front. Immunol. 2018, 9, 298. [Google Scholar] [CrossRef]
- Picascia, A.; Grimaldi, V.; Pignalosa, O.; De Pascale, M.R.; Schiano, C.; Napoli, C. Epigenetic control of autoimmune diseases: From bench to bedside. Clin. Immunol. 2015, 157, 1–15. [Google Scholar] [CrossRef]
- Klein, K.; Gay, S. Epigenetics in rheumatoid arthritis. Curr. Opin. Rheumatol. 2015, 27, 76–82. [Google Scholar] [CrossRef] [Green Version]
- Strietholt, S.; Maurer, B.; Peters, M.A.; Pap, T.; Gay, S. Epigenetic modifications in rheumatoid arthritis. Arthritis Res. Ther. 2008, 10, 219. [Google Scholar] [CrossRef]
- Chabhoub, G. Epigenetic targets of rheumatoid arthritis. World J. Rheumatol. 2015, 5, 127–130. [Google Scholar] [CrossRef]
- Briggs, S.D.; Xiao, T.; Sun, Z.W.; Caldwell, J.A.; Shabanowitz, J.; Hunt, D.F.; Allis, C.D.; Strahl, B.D. Gene silencing: Trans-histone regulatory pathway in chromatin. Nature 2002, 418, 498. [Google Scholar] [CrossRef]
- Jüngel, A.; Baresova, V.; Ospelt, C.; Simmen, B.R.; Michel, B.A.; Gay, R.E.; Gay, S.; Seemayer, C.A.; Neidhart, M. Trichostatin A sensitises rheumatoid arthritis synovial fibroblasts for TRAIL-induced apoptosis. Ann. Rheum. Dis. 2006, 65, 910–912. [Google Scholar] [CrossRef] [PubMed]
- Grabiec, A.M.; Krausz, S.; de Jager, W.; Burakowski, T.; Groot, D.; Sanders, M.E.; Prakken, B.J.; Maslinski, W.; Eldering, E.; Tak, P.P.; et al. Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J. Immunol. 2010, 184, 2718–2728. [Google Scholar] [CrossRef]
- Lin, H.S.; Hu, C.Y.; Chan, H.Y.; Liew, Y.Y.; Huang, H.P.; Lepescheux, L.; Bastianelli, E.; Baron, R.; Rawadi, G.; Clément-Lacroix, P. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 2007, 150, 862–872. [Google Scholar] [CrossRef] [PubMed]
- Nasu, Y.; Nishida, K.; Miyazawa, S.; Komiyama, T.; Kadota, Y.; Abe, N.; Yoshida, A.; Hirohata, S.; Ohtsuka, A.; Ozaki, T. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarth. Cartil. 2008, 16, 723–732. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Saouaf, S.J.; Li, B.; Zhang, G.; Shen, Y.; Furuuchi, N.; Hancock, W.W.; Greene, M.I. Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp. Mol. Pathol. 2009, 87, 99–104. [Google Scholar] [CrossRef] [Green Version]
- Kouzarides, T. Chromatin modifications and their function. Cell 2007, 128, 693–705. [Google Scholar] [CrossRef]
- Trenkmann, M.; Brock, M.; Gay, R.E.; Kolling, C.; Speich, R.; Michel, B.A.; Gay, S.; Huber, L.C. Expression and function of EZH2 in synovial fibroblasts: Epigenetic repression of the Wnt inhibitor SFRP1 in rheumatoid arthritis. Ann. Rheum. Dis. 2011, 70, 1482–1488. [Google Scholar] [CrossRef]
- Meinecke, I.; Cinski, A.; Baier, A.; Peters, M.A.; Dankbar, B.; Wille, A.; Drynda, A.; Mendoza, H.; Gay, R.E.; Hay, R.T.; et al. Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts. Proc. Natl. Acad. Sci. USA 2007, 104, 5073–5078. [Google Scholar] [CrossRef] [Green Version]
- Maciejewska-Rodrigues, H.; Karouzakis, E.; Strietholt, S.; Hemmatazad, H.; Neidhart, M.; Ospelt, C.; Gay, R.E.; Michel, B.A.; Pap, T.; Gay, S.; et al. Epigenetics and rheumatoid arthritis: The role of SENP1 in the regulation of MMP-1 expression. J. Autoimmun. 2010, 35, 15–22. [Google Scholar] [CrossRef] [Green Version]
- Glant, T.T.; Mikecz, K.; Rauch, T.A. Epigenetics in the pathogenesis of rheumatoid arthritis. BMC Med. 2014, 12, 35–39. [Google Scholar] [CrossRef]
- Glant, T.T.; Besenyei, T.; Kádár, A.; Kurkó, J.; Tryniszewska, B.; Gál, J.; Soós, G.; Szekanecz, Z.; Hoffmann, G.; Block, J.A.; et al. Differentially expressed epigenome modifiers, including aurora kinases A and B, in immune cells in rheumatoid arthritis in humans and mouse models. Arthritis Rheum. 2013, 65, 1725–1735. [Google Scholar] [CrossRef]
- Jones, P.A. Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 2012, 13, 484–492. [Google Scholar] [CrossRef]
- Turek-Plewa, J.; Jagodziński, P.P. The role of mammalian DNA methyltransferases in the regulation of gene expression. Cell Mol. Biol. Lett. 2005, 10, 631–647. [Google Scholar] [PubMed]
- Liu, C.C.; Fang, T.J.; Ou, T.T.; Wu, C.C.; Li, R.N.; Lin, Y.C.; Lin, C.H.; Tsai, W.C.; Liu, H.W.; Yen, J.H. Global DNA methylation, DNMT1, and MBD2 in patients with rheumatoid arthritis. Immunol. Lett. 2011, 135, 96–99. [Google Scholar] [CrossRef] [PubMed]
- Nakano Whitaker, J.W.; Boyle, D.L.; Wang, W.; Firestein, G.S. DNA methylome signature in rheumatoid arthritis. Ann. Rheum. Dis. 2013, 72, 110–117. [Google Scholar] [CrossRef] [PubMed]
- Richardson, B.; Scheinbart, L.; Strahler, J.; Gross, L.; Hanash, S.; Johnson, M. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 1990, 33, 1665–1673. [Google Scholar] [CrossRef] [PubMed]
- Fu, L.H.; Ma, C.L.; Cong, B.; Li, S.J.; Chen, H.Y.; Zhang, J.G. Hypomethylation of proximal CpG motif of interleukin-10 promoter regulates its expression in human rheumatoid arthritis. Acta. Pharmacol. Sin. 2011, 32, 1373–1380. [Google Scholar] [CrossRef] [Green Version]
- Nile, C.J.; Read, R.C.; Akil, M.; Duff, G.W.; Wilson, A.G. Methylation status of a single CpG site in the IL6 promoter is related to IL6 messenger RNA levels and rheumatoid arthritis. Arthritis Rheum. 2008, 58, 2686–2693. [Google Scholar] [CrossRef]
- Karouzakis, E.; Rengel, Y.; Jüngel, A.; Kolling, C.; Gay, R.E.; Michel, B.A.; Tak, P.P.; Gay, S.; Neidhart, M.; Ospelt, C. DNA methylation regulates the expression of CXCL12 in rheumatoid arthritis synovial fibroblasts. Genes Immun. 2011, 12, 643–652. [Google Scholar] [CrossRef] [Green Version]
- Neidhart, M.; Rethage, J.; Kuchen, S.; Künzler, P.; Crowl, R.M.; Billingham, M.E.; Gay, R.E.; Gay, S. Retrotransposable L1 elements expressed in rheumatoid arthritis synovial tissue: Association with genomic DNA hypomethylation and influence on gene expression. Arthritis Rheum. 2000, 43, 2634–2647. [Google Scholar] [CrossRef]
- Takami, N.; Osawa, K.; Miura, Y.; Komai, K.; Taniguchi, M.; Shiraishi, M.; Sato, K.; Iguchi, T.; Shiozawa, K.; Hashiramoto, A.; et al. Hypermethylated promoter region of DR3, the death receptor 3 gene, in rheumatoid arthritis synovial cells. Arthritis Rheum. 2006, 54, 779–787. [Google Scholar] [CrossRef]
- Lefèvre, S.; Knedla, A.; Tennie, C.; Kampmann, A.; Wunrau, C.; Dinser, R.; Korb, A.; Schnäker, E.M.; Tarner, I.H.; Robbins, P.D.; et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat. Med. 2009, 15, 1414–1420. [Google Scholar] [CrossRef] [Green Version]
- Ospelt, C.; Gay, S. The role of resident synovial cells in destructive arthritis. Best Pract. Res. Clin. Rheumatol. 2008, 22, 239–252. [Google Scholar] [CrossRef]
- Stanczyk, J.; Pedrioli, D.M.; Brentano, F.; Sanchez-Pernaute, O.; Kolling, C.; Gay, R.E.; Detmar, M.; Gay, S.; Kyburz, D. Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 2008, 58, 1001–1009. [Google Scholar] [CrossRef]
- Wang, Z.; Chang, C.; Peng, M.; Lu, Q. Translating epigenetics into clinic: Focus on lupus. Clin. Epigenet. 2017, 9, 78. [Google Scholar] [CrossRef]
- Balada, E.; Ordi-Ros, J.; Serrano-Acedo, S.; Martinez-Lostao, L.; Vilardell-Tarrés, M. Transcript overexpression of the MBD2 and MBD4 genes in CD4+ T cells from systemic lupus erythematosus patients. J. Leukoc. Biol. 2007, 81, 1609–1616. [Google Scholar] [CrossRef]
- Balada, E.; Ordi-Ros, J.; Serrano-Acedo, S.; Martinez-Lostao, L.; Rosa-Leyva, M.; Vilardell-Tarrés, M. Transcript levels of DNA methyltransferases DNMT1, DNMT3A and DNMT3B in CD4+ T cells from patients with systemic lupus erythematosus. Immunology 2008, 124, 339–347. [Google Scholar] [CrossRef]
- Deng, C.; Kaplan, M.J.; Yang, J.; Ray, D.; Zhang, Z.; McCune, W.J.; Hanash, S.M.; Richardson, B.C. Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum. 2001, 44, 397–407. [Google Scholar] [CrossRef]
- Deng, C.; Lu, Q.; Zhang, Z.; Rao, T.; Attwood, J.; Yung, R.; Richardson, B. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum. 2003, 48, 746–756. [Google Scholar] [CrossRef]
- Luo, Y.; Li, Y.; Su, Y.; Yin, H.; Hu, N.; Wang, S.; Lu, Q. Abnormal DNA methylation in T cells from patients with subacute cutaneous lupus erythematosus. Br. J. Dermatol. 2008, 159, 827–833. [Google Scholar] [CrossRef] [PubMed]
- Lu, Q.; Kaplan, M.; Ray, D.; Ray, D.; Zacharek, S.; Gutsch, D.; Richardson, B. Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum. 2002, 46, 1282–1291. [Google Scholar] [CrossRef] [PubMed]
- Oelke, K.; Lu, Q.; Richardson, D.; Wu, A.; Deng, C.; Hanash, S.; Richardson, B. Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis Rheum. 2004, 50, 1850–1860. [Google Scholar] [CrossRef] [Green Version]
- Basu, D.; Liu, Y.; Wu, A.; Yarlagadda, S.; Gorelik, G.J.; Kaplan, M.J.; Hewagama, A.; Hinderer, R.C.; Strickland, F.M.; Richardson, B.C. Stimulatory and inhibitory killer Ig-like receptor molecules are expressed and functional on lupus T cells. J. Immunol. 2009, 183, 3481–3487. [Google Scholar] [CrossRef]
- Coit, P.; Jeffries, M.; Altorok, N.; Dozmorov, M.G.; Koelsch, K.A.; Wren, J.D.; Merrill, J.T.; McCune, W.J.; Sawalha, A.H. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naïve CD4+ T cells from lupus patients. J. Autoimmun. 2013, 43, 78–84. [Google Scholar] [CrossRef]
- Richardson, B.C.; Strahler, J.R.; Pivirotto, T.S.; Quddus, J.; Bayliss, G.E.; Gross, L.A.; O’Rourke, K.S.; Powers, D.; Hanash, S.M.; Johnson, M.A. Phenotypic and functional similarities between 5-azacytidine-treated T cells and a T cell subset in patients with active systemic lupus erythematosus. Arthritis Rheum. 1992, 35, 647–662. [Google Scholar] [CrossRef]
- Strickland, F.M.; Richardson, B.C. Epigenetics in autoimmunity—DNA methylation in systemic lupus erythematosus and beyond. Autoimmunity 2008, 41, 278–286. [Google Scholar] [CrossRef]
- Mi, X.B.; Zeng, F.Q. Hypomethylation of interleukin-4 and -6 promoters in T cells from systemic lupus erythematosus patients. Acta Pharmacol. Sin. 2008, 29, 105–112. [Google Scholar] [CrossRef] [Green Version]
- Deng, Y.; Zhao, J.; Sakurai, D.; Kaufman, K.M.; Edberg, J.C.; Kimberly, R.P.; Kamen, D.L.; Gilkeson, G.S.; Jacob, C.O.; Scofield, R.H.; et al. MicroRNA-3148 modulates allelic expression of toll-like receptor 7 variant associated with systemic lupus erythematosus. PLoS Genet. 2013, 9, e1003336. [Google Scholar] [CrossRef]
- Javierre, B.M.; Fernandez, A.F.; Richter, J.; Al-Shahrour, F.; Martin-Subero, J.I.; Rodriguez-Ubreva, J.; Berdasco, M.; Fraga, M.F.; O’Hanlon, T.P.; Rider, L.G.; et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res. 2010, 20, 170–179. [Google Scholar] [CrossRef]
- Pieterse, E.; Hofstra, J.; Berden, J.; Herrmann, M.; Dieker, J.; van der Vlag, J. Acetylated histones contribute to the immunostimulatory potential of neutrophil extracellular traps in systemic lupus erythematosus. Clin. Exp. Immunol. 2015, 179, 68–74. [Google Scholar] [CrossRef]
- Zhang, Z.; Song, L.; Maurer, K.; Petri, M.A.; Sullivan, K.E. Global H4 acetylation analysis by ChIP-chip in systemic lupus erythematosus monocytes. Genes Immun. 2010, 11, 124–133. [Google Scholar] [CrossRef] [PubMed]
- Zhan, Y.; Guo, Y.; Lu, Q. Aberrant epigenetic regulation in the pathogenesis of systemic lupus erythematosus and its implication in precision medicine. Cytogenet. Genome Res. 2016, 149, 141–155. [Google Scholar] [CrossRef] [PubMed]
- Gray, S.G. Perspectives on epigenetic-based immune intervention for rheumatic diseases. Arthritis Res. Ther. 2013, 15, 207. [Google Scholar] [CrossRef]
- Hedrich, C.M.; Rauen, T.; Apostolidis, S.A.; Grammatikos, A.P.; Rodriguez, N.; Ioannidis, C.; Kyttaris, V.C.; Crispin, J.C.; Tsokos, G.C. Stat3 promotes IL-10 expression in lupus T cells through trans-activation and chromatin remodeling. Proc. Natl. Acad. Sci. USA 2014, 111, 13457–13462. [Google Scholar] [CrossRef] [PubMed]
- Zhou, Y.; Qiu, X.; Luo, Y.; Yuan, J.; Li, Y.; Zhong, Q.; Zhao, M.; Lu, Q. Histone modifications and methyl-CpG-binding domain protein levels at the TNFSF7 (CD70) promoter in SLE CD4+ T cells. Lupus 2011, 20, 1365–1371. [Google Scholar] [CrossRef]
- Dai, Y.; Huang, Y.S.; Tang, M.; Lv, T.Y.; Hu, C.X.; Tan, Y.H.; Xu, Z.M.; Yin, Y.B. Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus 2007, 16, 939–946. [Google Scholar] [CrossRef] [PubMed]
- Pan, W.; Zhu, S.; Yuan, M.; Cui, H.; Wang, L.; Luo, X.; Li, J.; Zhou, H.; Tang, Y.; Shen, N. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J. Immunol. 2010, 184, 6773–6781. [Google Scholar] [CrossRef]
- Zhao, S.; Wang, Y.; Liang, Y.; Zhao, M.; Long, H.; Ding, S.; Yin, H.; Lu, Q. MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum. 2011, 63, 1376–1386. [Google Scholar] [CrossRef]
- Chauhan, S.K.; Singh, V.V.; Rai, R.; Rai, M.; Rai, G. Differential microRNA profile and post-transcriptional regulation exist in systemic lupus erythematosus patients with distinct autoantibody specificities. J. Clin. Immunol. 2014, 34, 491–503. [Google Scholar] [CrossRef]
- Peedicayil, J. Epigenetic drugs for multiple sclerosis. Curr. Neuropharmacol. 2016, 14, 3–9. [Google Scholar] [CrossRef]
- Rito, Y.; Torre-Villalvazo, I.; Flores, J.; Rivas, V.; Corona, T. Epigenetics in multiple sclerosis: Molecular mechanisms and dietary intervention. Cent. Nerv. Syst. Agents Med. Chem. 2018, 18, 8–15. [Google Scholar] [CrossRef]
- Babenko, O.; Kovalchuk, I.; Metz, G.A. Epigenetic programming of neurodegenerative diseases by an adverse environment. Brain Res. 2012, 1444, 96–111. [Google Scholar] [CrossRef]
- Meda, F.; Folci, M.; Baccarelli, A.; Selmi, C. The epigenetics of autoimmunity. Cell Mol. Immunol. 2011, 8, 226–236. [Google Scholar] [CrossRef] [Green Version]
- Casaccia-Bonnefil, P.; Pandozy, G.; Mastronardi, F. Evaluating epigenetic landmarks in the brain of multiple sclerosis patients: A contribution to the current debate on disease pathogenesis. Prog. Neurobiol. 2008, 86, 368–378. [Google Scholar]
- Huynh, J.L.; Garg, P.; Thin, T.H.; Yoo, S.; Dutta, R.; Trapp, B.D.; Haroutunian, V.; Zhu, J.; Donovan, M.J.; Sharp, A.J.; et al. Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains. Nat. Neurosci. 2014, 17, 121–130. [Google Scholar] [CrossRef]
- Mastronardi, F.G.; Noor, A.; Wood, D.D.; Paton, T.; Moscarello, M.A. Peptidyl argininedeiminase 2 CpG island in multiple sclerosis white matter is hypomethylated. J. Neurosci. Res. 2007, 85, 2006–2016. [Google Scholar] [CrossRef]
- Calabrese, R.; Zampieri, M.; Mechelli, R.; Annibali, V.; Guastafierro, T.; Ciccarone, F.; Coarelli, G.; Umeton, R.; Salvetti, M.; Caiafa, P. Methylation-dependent PAD2 upregulation in multiple sclerosis peripheral blood. Mult. Scler. 2012, 18, 299–304. [Google Scholar] [CrossRef]
- Guan, H.; Nagarkatti, P.S.; Nagarkatti, M. CD44 Reciprocally regulates the differentiation of encephalitogenic Th1/Th17 and Th2/regulatory T cells through epigenetic modulation involving DNA methylation of cytokine gene promoters, thereby controlling the development of experimental autoimmune encephalomyelitis. J. Immunol. 2011, 186, 6955–6964. [Google Scholar] [PubMed]
- Iridoy Zulet, M.; Pulido Fontes, L.; Ayuso Blanco, T.; Lacruz Bescos, F.; Mendioroz Iriarte, M. Epigenetic changes in neurology: DNA methylation in multiple sclerosis. Neurologia 2017, 32, 463–468. [Google Scholar] [CrossRef] [PubMed]
- Pedre, X.; Mastronardi, F.; Bruck, W.; López-Rodas, G.; Kuhlmann, T.; Casaccia, P. Changed histone acetylation patterns in normal-appearing white matter and early multiple sclerosis lesions. J. Neurosci. 2011, 31, 3435–3445. [Google Scholar] [CrossRef]
- Sharma, P.; Azebi, S.; England, P.; Christensen, T.; Møller-Larsen, A.; Petersen, T.; Batsché, E.; Muchardt, C. Citrullination of histone H3 interferes with HP1-mediated transcriptional repression. PLoS Genet. 2012, 8, e1002934. [Google Scholar] [CrossRef] [PubMed]
- Junker, A.; Krumbholz, M.; Eisele, S.; Mohan, H.; Augstein, F.; Bittner, R.; Lassmann, H.; Wekerle, H.; Hohlfeld, R.; Meinl, E. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 2009, 132, 3342–3352. [Google Scholar] [CrossRef] [Green Version]
- Du, C.; Liu, C.; Kang, J.; Zhao, G.; Ye, Z.; Huang, S.; Li, Z.; Wu, Z.; Pei, G. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat. Immunol. 2009, 10, 1252–1259. [Google Scholar] [CrossRef]
- Koch, M.W.; Metz, L.M.; Kovalchuk, O. Epigenetic changes in patients with multiple sclerosis. Nat. Rev. Neurol. 2013, 9, 35–43. [Google Scholar] [CrossRef]
- Noorbakhsh, F.; Ellestad, K.K.; Maingat, F.; Warren, K.G.; Han, M.H.; Steinman, L.; Baker, G.B.; Power, C. Impaired neurosteroid synthesis in multiple sclerosis. Brain 2011, 134, 2703–2721. [Google Scholar] [CrossRef] [Green Version]
- O’Connell, R.M.; Kahn, D.; Gibson, W.S.; Round, J.L.; Scholz, R.L.; Chaudhuri, A.A.; Kahn, M.E.; Rao, D.S.; Baltimore, D. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 2010, 33, 607–619. [Google Scholar] [CrossRef] [PubMed]
- Fu, Y.; Li, Y.; Xu, L.; Liu, S.; Wang, M.; Xiao, L.; Liu, S.; Dai, Y. Immunology repertoire study of pulmonary sarcoidosis T cells in CD4+, CD8+ PBMC and tissue. Oncotarget 2017, 8, 89515–89526. [Google Scholar] [CrossRef] [Green Version]
- Talreja, J.; Talwar, H.; Ahmad, N.; Rastogi, R.; Samavati, L. Dual inhibition of Rip2 and IRAK1/4 regulates IL-1β and IL-6 in sarcoidosis alveolar macrophages and peripheral blood mononuclear cells. J. Immunol. 2016, 197, 1368–1378. [Google Scholar] [CrossRef] [PubMed]
- Chopra, A.; Kalkanis, A.; Judson, M.A. Biomarkers in sarcoidosis. Expert Rev. Clin. Immunol. 2016, 12, 1191–1208. [Google Scholar] [CrossRef]
- Bargagli, E.; Bianchi, N.; Margollicci, M.; Olivieri, C.; Luddi, A.; Coviello, G.; Grosso, S.; Rottoli, P. Chitotriosidase and soluble IL-2 receptor: Comparison of two markers of sarcoidosis severity. Scand. J. Clin. Lab. Invest. 2008, 68, 479–483. [Google Scholar] [CrossRef]
- Uysal, P.; Durmus, S.; Sozer, V.; Gelisgen, R.; Seyhan, E.C.; Erdenen, F.; Simsek, G.; Uzun, H. YKL-40, soluble IL-2 receptor, angiotensin converting enzyme and c-reactive protein: Comparison of markers of sarcoidosis activity. Biomolecules 2018, 8, 84. [Google Scholar] [CrossRef]
- Fischer, A.; Rybicki, B.A. Granuloma genes in sarcoidosis: What is new? Curr. Opin. Pulm. Med. 2015, 21, 510–516. [Google Scholar] [CrossRef] [PubMed]
- Becker, A.; Vella, G.; Galata, V.; Rentz, K.; Beisswenger, C.; Herr, C.; Walter, J.; Tierling, S.; Slevogt, H.; Keller, A.; et al. The composition of the pulmonary microbiota in sarcoidosis—An observational study. Respir. Res. 2019, 20, 46. [Google Scholar] [CrossRef] [PubMed]
- Celada, L.J.; Hawkins, C.; Drake, W.P. The etiologic role of infectious antigens in sarcoidosis pathogenesis. Clin. Chest Med. 2015, 36, 561–568. [Google Scholar] [CrossRef]
- Bilimoria, P.M.; Stevens, B. Microglia function during brain development: New insights from animal models. Brain Res. 2015, 1617, 7–17. [Google Scholar] [CrossRef] [PubMed]
- Mosser, C.A.; Baptista, S.; Arnoux, I.; Audinat, E. Microglia in CNS development: Shaping the brain for the future. Prog. Neurobiol. 2017, 149–150, 1–20. [Google Scholar] [CrossRef]
- Schafer, D.P.; Lehrman, E.K.; Kautzman, A.G.; Koyama, R.; Mardinly, A.R.; Yamasaki, R.; Ransohoff, R.M.; Greenberg, M.E.; Barres, B.A.; Stevens, B. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 2012, 74, 691–705. [Google Scholar] [CrossRef]
- Boya, P.; de la Rosa, E.J. Cell death in early neural life. Birth Defects Res. C Embryo Today 2005, 75, 281–293. [Google Scholar] [CrossRef]
- Wang, F.; Gómez-Sintes, R.; Boya, P. Lysosomal membrane permeabilization and cell death. Traffic 2018, 19, 918–931. [Google Scholar] [CrossRef]
- Colonna, M.; Butovsky, O. Microglia function in the central nervous system during health and neurodegeneration. Annu. Rev. Immunol. 2017, 35, 441–468. [Google Scholar] [CrossRef]
- Filiano, A.J.; Gadani, S.P.; Kipnis, J. Interactions of innate and adaptive immunity in brain development and function. Brain Res. 2015, 1617, 18–27. [Google Scholar] [CrossRef]
- Salam, A.P.; Borsini, A.; Zunszain, P.A. Trained innate immunity: A salient factor in the pathogenesis of neuroimmune psychiatric disorders. Mol. Psychiatry 2018, 23, 170–176. [Google Scholar] [CrossRef]
- Sandman, C.A.; Buss, C.; Head, K.; Davis, E.P. Fetal exposure to maternal depressive symptoms is associated with cortical thickness in late childhood. Biol. Psychiatry 2015, 77, 324–334. [Google Scholar] [CrossRef]
- Haley, M.J.; Brough, D.; Quintin, J.; Allan, S.M. Microglial priming as trained immunity in the brain. Neuroscience 2017, 405, 47–54. [Google Scholar] [CrossRef]
- Perry, V.H.; Holmes, C. Microglial priming in neurodegenerative disease. Nat. Rev. Neurol. 2014, 10, 217–224. [Google Scholar] [CrossRef]
- Bauman, M.D.; Iosif, A.M.; Smith, S.E.; Bregere, C.; Amaral, D.G.; Patterson, P.H. Activation of the maternal immune system during pregnancy alters behavioral development of rhesus monkey offspring. Biol. Psychiatry 2014, 75, 332–341. [Google Scholar] [CrossRef]
- Rose, D.R.; Careaga, M.; Van de Water, J.; McAllister, K.; Bauman, M.D.; Ashwood, P. Long-term altered immune responses following fetal priming in a non-human primate model of maternal immune activation. Brain Behav. Immun. 2017, 63, 60–70. [Google Scholar] [CrossRef]
- Missault, S.; Van den Eynde, K.; Vanden Berghe, W.; Fransen, E.; Weeren, A.; Timmermans, J.P.; Kumar-Singh, S.; Dedeurwaerdere, S. The risk for behavioural deficits is determined by the maternal immune response to prenatal immune challenge in a neurodevelopmental model. Brain Behav. Immun. 2014, 42, 138–146. [Google Scholar] [CrossRef]
- Levy, O.; Wynn, J.L. A prime time for trained immunity: Innate immune memory in newborns and infants. Neonatology 2014, 105, 136–141. [Google Scholar] [CrossRef]
- Püntener, U.; Booth, S.G.; Perry, V.H.; Teeling, J.L. Long-term impact of systemic bacterial infection on the cerebral vasculature and microglia. J. Neuroinflamm. 2012, 9, 146. [Google Scholar] [CrossRef]
- Amitai, M.; Taler, M.; Carmel, M.; Michaelovsky, E.; Eilat, T.; Yablonski, M.; Orpaz, N.; Chen, A.; Apter, A.; Weizman, A.; et al. The relationship between plasma cytokine levels and response to selective serotonin reuptake inhibitor treatment in children and adolescents with depression and/or anxiety disorders. J. Child Adolesc. Psychopharmacol. 2016, 26, 727–732. [Google Scholar] [CrossRef]
- Pérez-Sánchez, G.; Becerril-Villanueva, E.; Arreola, R.; Martínez-Levy, G.; Hernández-Gutiérrez, M.E.; Velasco-Velásquez, M.A.; Alvarez-Herrera, S.; Cruz-Fuentes, C.; Palacios, L.; de la Peña, F.; et al. Inflammatory profiles in depressed adolescents treated with fluoxetine: An 8-week follow-up open study. Mediators Inflamm. 2018, 2018, 4074051. [Google Scholar] [CrossRef]
- Wang, S.; Colonna, M. Microglia in Alzheimer’s disease: A target for immunotherapy. J. Leukoc. Biol. 2019, 1–9. [Google Scholar] [CrossRef]
- Deming, Y.; Li, Z.; Benitez, B.A.; Cruchaga, C. Triggering receptor expressed on myeloid cells 2 (TREM2): A potential therapeutic target for Alzheimer disease? Expert Opin. Ther. Targets 2018, 22, 587–598. [Google Scholar] [CrossRef]
- Bradshaw, E.M.; Chibnik, L.B.; Keenan, B.T.; Ottoboni, L.; Raj, T.; Tang, A.; Rosenkrantz, L.L.; Imboywa, S.; Lee, M.; Von Korff, A.; et al. CD33 Alzheimer’s disease locus: Altered monocyte function and amyloid biology. Nat. Neurosci. 2013, 16, 848–850. [Google Scholar] [CrossRef]
- Sfera, A.; Gradini, R.; Cummings, M.; Diaz, E.; Price, A.I.; Osorio, C. Rusty microglia: Trainers of innate immunity in Alzheimer’s disease. Front. Neurol. 2018, 9, 1062. [Google Scholar] [CrossRef]
- Liddelow, S.A.; Guttenplan, K.A.; Clarke, L.E.; Bennett, F.C.; Bohlen, C.J.; Schirmer, L.; Bennett, M.L.; Münch, A.E.; Chung, W.S.; Peterson, T.C.; et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 2017, 541, 481–487. [Google Scholar] [CrossRef]
- Liu, X.; Jiao, B.; Shen, L. The epigenetics of Alzheimer’s disease: Factors and therapeutic implications. Front. Genet. 2018, 9, 579. [Google Scholar] [CrossRef]
- Zhang, C.C.; Xing, A.; Tan, M.S.; Tan, L.; Yu, J.T. The role of MAPT in neurodegenerative diseases: Genetics, mechanisms and therapy. Mol. Neurobiol. 2016, 7, 4893–4904. [Google Scholar] [CrossRef]
- De Calignon, A.; Fox, L.M.; Pitstick, R.; Carlson, G.A.; Bacskai, B.J.; Spires-Jones, T.L.; Hyman, B.T. Caspase activation precedes and leads to tangles. Nature 2010, 7292, 1201–1204. [Google Scholar] [CrossRef] [PubMed]
- Iovino, M.; Agathou, S.; González-Rueda, A.; Del Castillo Velasco-Herrera, M.; Borroni, B.; Alberici, A.; Lynch, T.; O’Dowd, S.; Geti, I.; Gaffney, D.; et al. Early maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients with MAPT mutations. Brain 2015, 138, 3345–3359. [Google Scholar] [CrossRef]
- Campagna, J.; Spilman, P.; Jagodzinska, B.; Bai, D.; Hatami, A.; Zhu, C.; Bilousova, T.; Jun, M.; Elias, C.J.; Pham, J.; et al. A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer’s disease mouse model. Sci. Rep. 2018, 1, 17574. [Google Scholar] [CrossRef]
- Cohen, T.J.; Guo, J.L.; Hurtado, D.E.; Kwong, L.K.; Mills, I.P.; Trojanowski, J.Q.; Lee, V.M. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun. 2011, 2, 252. [Google Scholar] [CrossRef]
- Julien, C.; Tremblay, C.; Emond, V.; Lebbadi, M.; Salem, N., Jr.; Bennett, D.A.; Calon, F. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2009, 1, 48–58. [Google Scholar] [CrossRef]
- Ammal Kaidery, N.; Thomas, B. Current perspective of mitochondrial biology in Parkinson’s disease. Neurochem. Int. 2018, 117, 91–113. [Google Scholar] [CrossRef]
- Schneider, R.B.; Iourinets, J.; Richard, I.H. Parkinson’s disease psychosis: Presentation, diagnosis and management. Neurodegener. Dis. Manag. 2017, 7, 365–376. [Google Scholar] [CrossRef]
- Wong, Y.C.; Krainc, D. α-synuclein toxicity in neurodegeneration: Mechanism and therapeutic strategies. Nat. Med. 2017, 23, 1–13. [Google Scholar] [CrossRef]
- Jiang, T.; Li, G.; Xu, J.; Gao, S.; Chen, X. The challenge of the pathogenesis of Parkinson’s disease: Is autoimmunity the culprit? Front. Immunol. 2018, 9, 2047. [Google Scholar] [CrossRef]
- Fourgeaud, L.; Través, P.G.; Tufail, Y.; Leal-Bailey, H.; Lew, E.D.; Burrola, P.G.; Callaway, P.; Zagórska, A.; Rothlin, C.V.; Nimmerjahn, A.; et al. TAM receptors regulate multiple features of microglial physiology. Nature 2016, 532, 240–244. [Google Scholar] [CrossRef] [Green Version]
- Ji, R.; Tian, S.; Lu, H.J.; Lu, Q.; Zheng, Y.; Wang, X.; Ding, J.; Li, Q.; Lu, Q. TAM receptors affect adult brain neurogenesis by negative regulation of microglial cell activation. J. Immunol. 2013, 191, 6165–6177. [Google Scholar] [CrossRef] [PubMed]
- Matsumoto, L.; Takuma, H.; Tamaoka, A.; Kurisaki, H.; Date, H.; Tsuji, S.; Iwata, A. CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson’s disease. PLoS ONE 2010, 11, e15522. [Google Scholar] [CrossRef] [PubMed]
- Jowaed, A.; Schmitt, I.; Kaut, O.; Wüllner, U. Methylation regulates alpha-synuclein expression and is decreased in Parkinson’s disease patients’ brains. J. Neurosci. 2010, 18, 6355–6359. [Google Scholar] [CrossRef]
- Desplats, P.; Spencer, B.; Coffee, E.; Patel, P.; Michael, S.; Patrick, C.; Adame, A.; Rockenstein, E.; Masliah, E. Alpha-synuclein sequesters Dnmt1 from the nucleus: A novel mechanism for epigenetic alterations in Lewy body diseases. J. Biol. Chem. 2011, 11, 9031–9037. [Google Scholar] [CrossRef]
- Hess, M.E.; Hess, S.; Meyer, K.D.; Verhagen, L.A.; Koch, L.; Brönneke, H.S.; Dietrich, M.O.; Jordan, S.D.; Saletore, Y.; Elemento, O.; et al. The fat mass and obesity associated gene (Fto) regulates activity of the dopaminergic midbrain circuitry. Nat. Neurosci. 2013, 16, 1042–1048. [Google Scholar] [CrossRef]
- Labbé, C.; Lorenzo-Betancor, O.; Ross, O.A. Epigenetic regulation in Parkinson’s disease. Acta Neuropathol. 2016, 132, 515–530. [Google Scholar] [CrossRef] [PubMed]
- Harrison, I.F.; Dexter, D.T. Epigenetic targeting of histone deacetylase: Therapeutic potential in Parkinson’s disease? Pharmacol. Ther. 2013, 140, 34–52. [Google Scholar] [CrossRef] [PubMed]
- Feng, Y.; Jankovic, J.; Wu, Y.C. Epigenetic mechanisms in Parkinson’s disease. J. Neurol. Sci. 2015, 349, 3–9. [Google Scholar] [CrossRef]
- Choi, D.C.; Yoo, M.; Kabaria, S.; Junn, E. MicroRNA-7 facilitates the degradation of alpha-synuclein and its aggregates by promoting autophagy. Neurosci. Lett. 2018, 678, 118–123. [Google Scholar] [CrossRef] [PubMed]
- Junn, E.; Lee, K.W.; Jeong, B.S.; Chan, T.W.; Im, J.Y.; Mouradian, M.M. Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc. Natl. Acad. Sci. USA 2009, 31, 13052–13057. [Google Scholar] [CrossRef]
- Doxakis, E. Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J. Biol. Chem. 2010, 17, 12726–12734. [Google Scholar] [CrossRef] [PubMed]
- Kleijer, K.T.E.; Huguet, G.; Tastet, J.; Bourgeron, T.; Burbach, J.P.H. Anatomy and cell biology of autism spectrum disorder: Lessons from human genetics. Adv. Anat. Embryol. Cell Biol. 2017, 224, 1–25. [Google Scholar] [PubMed]
- Bourgeron, T. Current knowledge on the genetics of autism and propositions for future research. C. R. Biol. 2016, 339, 300–307. [Google Scholar] [CrossRef] [PubMed]
- Chahrour, M.; O’Roak, B.J.; Santini, E.; Samaco, R.C.; Kleiman, R.J.; Manzini, M.C. Current perspectives in autism spectrum disorder: From genes to therapy. J. Neurosci. 2016, 36, 11402–11410. [Google Scholar] [CrossRef] [PubMed]
- Huguet, G.; Ey, E.; Bourgeron, T. The genetic landscapes of autism spectrum disorders. Annu. Rev. Genom. Hum. Genet. 2013, 14, 191–213. [Google Scholar] [CrossRef] [PubMed]
- Toro, R.; Konyukh, M.; Delorme, R.; Leblond, C.; Chaste, P.; Fauchereau, F.; Coleman, M.; Leboyer, M.; Gillberg, C.; Bourgeron, T. Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. Trends Genet. 2010, 26, 363–372. [Google Scholar] [CrossRef] [Green Version]
- McDougle, C.J.; Landino, S.M.; Vahabzadeh, A.; O’Rourke, J.; Zurcher, N.R.; Finger, B.C.; Palumbo, M.L.; Helt, J.; Mullett, J.E.; Hooker, J.M.; et al. Toward an immune-mediated subtype of autism spectrum disorder. Brain Res. 2015, 1617, 72–92. [Google Scholar] [CrossRef]
- Capuron, L.; Miller, A.H. Immune system to brain signaling: Neuropsychopharmacological implications. Pharmacol. Ther. 2011, 130, 226–238. [Google Scholar] [CrossRef] [Green Version]
- Horder, J.; Petrinovic, M.M.; Mendez, M.A.; Bruns, A.; Takumi, T.; Spooren, W.; Barker, G.J.; Künnecke, B.; Murphy, D.G. Glutamate and GABA in autism spectrum disorder-a translational magnetic resonance spectroscopy study in man and rodent models. Transl. Psychiatry 2018, 8, 106. [Google Scholar] [CrossRef] [PubMed]
- Masi, A.; Glozier, N.; Dale, R.; Guastella, A.J. The immune system, cytokines, and biomarkers in autism spectrum disorder. Neurosci. Bull. 2017, 33, 194–204. [Google Scholar] [CrossRef] [PubMed]
- Krakowiak, P.; Goines, P.E.; Tancredi, D.J.; Ashwood, P.; Hansen, R.L.; Hertz-Picciotto, I.; Van de Water, J. Neonatal cytokine profiles associated with autism spectrum disorder. Biol. Psychiatry 2017, 81, 442–451. [Google Scholar] [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Włodarczyk, M.; Druszczyńska, M.; Fol, M. Trained Innate Immunity Not Always Amicable. Int. J. Mol. Sci. 2019, 20, 2565. https://doi.org/10.3390/ijms20102565
Włodarczyk M, Druszczyńska M, Fol M. Trained Innate Immunity Not Always Amicable. International Journal of Molecular Sciences. 2019; 20(10):2565. https://doi.org/10.3390/ijms20102565
Chicago/Turabian StyleWłodarczyk, Marcin, Magdalena Druszczyńska, and Marek Fol. 2019. "Trained Innate Immunity Not Always Amicable" International Journal of Molecular Sciences 20, no. 10: 2565. https://doi.org/10.3390/ijms20102565